Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Acerta Pharma BV
Dana-Farber Cancer Institute
Canadian Cancer Trials Group
Memorial Sloan Kettering Cancer Center
Pfizer
Assistance Publique - Hôpitaux de Paris
ADC Therapeutics S.A.
Taiho Oncology, Inc.
National Cancer Institute (NCI)
Children's Cancer Group, China
Fate Therapeutics
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Janssen Biotech, Inc.
University of California, Davis
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Stichting Hemato-Oncologie voor Volwassenen Nederland
M.D. Anderson Cancer Center
Innovent Biologics (Suzhou) Co. Ltd.
University Health Network, Toronto
Allogene Therapeutics
M.D. Anderson Cancer Center
BeOne Medicines
M.D. Anderson Cancer Center
Dartmouth-Hitchcock Medical Center
Seattle Children's Hospital
Hoffmann-La Roche